Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation concerning potential securities fraud or unlawful business practices. The investigation follows Omeros's June 26, 2026 announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy. On that news, Omeros's stock price fell $2.05 per share, or 19.12%, to close at $8.67 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
Omeros CorporationNegative CHMP opinion on narsoplimab MAA for HSCT-TMA, causing 19% stock drop.